ADC FG-3246 May Show Promise in Advanced Prostate Cancer

Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.

Related Keywords

Deyaa Adib ,Rahul Aggarwal ,Fibrogen Inc ,National Cancer Institute ,University Of California San Francisco ,Astrazeneca ,Key Part ,Prostate Cancer ,Prostate Specific Antigen ,Why Is It Important For Patients ,California San Francisco ,